What is that common "issue."
If it is failing phase 3 trials, that's not unique to stem cell companies. That's drug development in general.
If it is post hoc analysis, I would remind you that our big problem has been failing primary endpoints when looking at entire cohorts. We have shown statistically significant results on pre-specified subgroups, and also across entire cohorts for some secondary endpoints. This is not post hoc analysis.
Any post hoc analysis we have done has been clearly labeled as exloratory.
Cell Therapy News/Articles, page-13550
-
- There are more pages in this discussion • 4,890 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.82 |
Change
0.290(19.0%) |
Mkt cap ! $2.009B | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.82 | $1.71 | $13.18M | 7.493M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 61662 | $1.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 30543 | 4 |
View Market Depth
| Last trade - 11.06am 14/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |